Weighted Average Number of Shares Outstanding, Diluted of Amneal Pharmaceuticals, Inc. from 30 Sep 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Amneal Pharmaceuticals, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Sep 2018 to 31 Dec 2025.
  • Amneal Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 31 Dec 2025 was 324,805,000, a 5.1% increase year-over-year.
  • Amneal Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2025 was 324,805,000, a 5.1% increase from 2024.
  • Amneal Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 308,978,000, a 75% increase from 2023.
  • Amneal Pharmaceuticals, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 176,136,000, a 17% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Amneal Pharmaceuticals, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 324,805,000 +15,827,000 +5.1% 01 Oct 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
Q3 2025 324,754,000 +15,107,000 +4.9% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 322,363,000 +3,406,000 +1.1% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 323,961,000 +16,682,000 +5.4% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 308,978,000 +132,842,000 +75% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
Q3 2024 309,647,000 +149,956,000 +94% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 318,957,000 +164,070,000 +106% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 307,279,000 +155,170,000 +102% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 176,136,000 +25,192,000 +17% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2026 2025 FY
Q3 2023 159,691,000 +8,298,000 +5.5% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 154,887,000 +3,894,000 +2.6% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 152,109,000 +2,217,000 +1.5% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 150,944,000 -877,000 -0.58% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
Q3 2022 151,393,000 +2,103,000 +1.4% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 150,993,000 -993,000 -0.65% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 149,892,000 -1,328,000 -0.88% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 151,821,000 +2,908,000 +2% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q3 2021 149,290,000 +1,732,000 +1.2% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 151,986,000 +4,594,000 +3.1% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 151,220,000 +3,264,000 +2.2% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 148,913,000 +16,807,000 +13% 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2023 2022 FY
Q3 2020 147,558,000 +16,829,000 +13% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 147,392,000 +19,376,000 +15% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 147,956,000 +20,269,000 +16% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 132,106,000 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 130,729,000 +2,507,000 +2% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 128,016,000 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 127,687,000 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q3 2018 128,222,000 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3

Amneal Pharmaceuticals, Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 324,805,000 +15,827,000 +5.1% 01 Jan 2025 31 Dec 2025 10-K 27 Feb 2026 2025 FY
2024 308,978,000 +132,842,000 +75% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2026 2025 FY
2023 176,136,000 +25,192,000 +17% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2026 2025 FY
2022 150,944,000 -877,000 -0.58% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
2021 151,821,000 +2,908,000 +2% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024 2023 FY
2020 148,913,000 +16,807,000 +13% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 132,106,000 +4,854,000 +3.8% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 127,252,000 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.